

**ABSTRACT OF THE DISCLOSURE:**

The invention concerns novel coagulation factor VII variants, wherein the Leu residue in  
5 position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by  
another amino acid residue which can be encoded by nucleic acid constructs and,  
optionally, wherein at least one other amino acid residue in the remaining positions in the  
protease domain has been replaced by another amino acid residue which can be encoded  
by nucleic acid constructs;  
10 with the proviso that the variant is not FVII(Ala305).

The invention further concerns nucleic acids encoding the Factor VII variants; vectors and  
cells comprising the nucleic acid; methods for producing the variants; pharmaceutical  
compositions comprising a Factor VII variant wherein the Leu residue in position 305 or the  
15 Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid  
residue which can be encoded by nucleic acid constructs and, optionally, wherein at least  
one other amino acid residue in the remaining positions in the protease domain has been  
replaced by another amino acid residue which can be encoded by nucleic acid constructs;  
use of the variants for producing a medicament for treatment or prophylaxis of bleeding  
20 disorders or enhancement of the coagulation system; and methods of treatment.

T0E050" 20T04B50